Introduction Biologic drugs are increasingly becoming important as therapeutics for treatment of various diseases, including cancer, infectious and inflammatory diseases. Classical antibody scaffolds and structures are being challenged by smaller but equally potent molecules which have several benefits over classical immunoglobulins. Camelid antibodies have been shown to lack the light chain only carrying effector function… Continue reading Nanobodies – A potent alternative
Introduction NGS is often used to explore the depths of the immune response against a given antigen and the cost of sequencing millions of antibodies is very low. The drawback is unfortunately, it is not possible and economically feasible to perform functional assays for millions of individual antibodies or clones, thus the typical approach is… Continue reading Using Sanger sequences to fish for antibodies in large NGS repertoires
With the increased throughput of single cell platforms and sequencing of immune repertoires, new challenges arise and the ability to map individual antibodies to its antigen is becoming increasingly important. What is LIBRA-seq? Mapping B cell receptor-antigen interaction at single cell level Dr. Georgiev’s group at the Vanderbilt University has developed a high-throughput, highly-multiplexed sequencing-based… Continue reading LIBRA-seq: accelerating antibody discovery
Biologics are becoming the drugs of choice when targeting cancers, infectious diseases etc. Monoclonal antibodies have taken up 6 out of 10 of the top selling drugs in the latter years and biologic drugs are expected to keep being some of the most efficient and potent drugs available. To find good drug candidates new sequencing… Continue reading NGS, Sanger & PacBio sequencing in Antibody Drug Discovery
non-antibody scaffolds from ERR3474167.fastq downloaded from the European Nucleotide Archive. These non-antibody scaffolds can make great therapeutics due to their small size although there can be tradeoffs.